MIM
AKBA icon

Monashee Investment Management’s Akebia Therapeutics AKBA Stock Holding History

Monashee Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,500,000
Closed -$2.88M – 60
2025
Q1 		$2.88M Buy
+1,500,000
New +$3.06M 0.34% 36
2018
Q2 		– Sell
-270,000
Closed -$149K – 160
2018
Q1 		$149K Buy
+270,000
New +$3.78M 0.04% 118
2017
Q3 		– Sell
-125,000
Closed -$1.8M – 84
2017
Q2 		$1.8M Buy
+125,000
New +$1.58M 0.76% 37

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Monashee Investment Management's AKBA Position: Q2 2025 in Review

Monashee Investment Management sold out of Akebia Therapeutics (AKBA) in Q2 2025, closing a stake of 1,500,000 shares — an estimated $2.88M sold.

Monashee Investment Management first reported a position in AKBA in Q2 2017 and held it in 3 quarters. The position peaked at $2.88M in Q1 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q2 2025.

  • Monashee Investment Management reported no remaining Akebia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Monashee Investment Management sold 1,500,000 Akebia Therapeutics shares in Q2 2025, an estimated $2.88M.
  • Monashee Investment Management first reported a position in Akebia Therapeutics in Q2 2017 and held it in 3 quarters.
  • Monashee Investment Management's Akebia Therapeutics position peaked at $2.88M in Q1 2025.
  • 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2025.

Based on Monashee Investment Management's 13F filing for Q2 2025, filed 11 Aug 2025.